New test for the detection of Omicron BA.x, BA.2 and Delta variants of SARS-CoV-2
09/03/2022
Routine COVID screening test that simultaneously detects and identifies the presence of Omicron BA.x, Omicron BA.2 and screens for other Delta variants.
Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in specialty in vitro medical diagnostics, announces the RUO (Research Use Only) launch of a new proprietary test, EBX 048, Eurobioplex SARS-CoV-2 Fast-SVT (Screening and VOC1 Typing), developedÌ specifically for routine COVID-19 screening and identification of current variants.
The proprietary EBX SARS-CoV-2 Fast-SVT is a real-time polymerase chain reaction (RT-PCR2) assay that, in a single test, identifies the presence of the SARS-CoV-2 virus and detect the K417N (Omicron variant BA.x sublineage screening), V213G (Omicron variant BA.2 sublineage screening) and L452R (Delta variant screening) mutations in a qualitative manner. The presence of the V213G mutation thus allows the BA.2 sublineage to be differentiated from other sublineages of the Omicron variant.
This new test, designed and developed by Eurobio Scientific's R&D department, is produced in-house, in its premises in Les Ulis - France and follows the ISO 13485 regulatory process. It is available in several versions allowing 50, 100 or 200 determinations to be performed simultaneously.